New drug ALN-ANG3 targets high cholesterol in early human trial

NCT ID NCT06452771

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called ALN-ANG3 in healthy adults with high cholesterol and triglycerides. The main goal is to check safety and side effects, not yet to see if it works. About 59 participants will receive either the drug or a placebo, and researchers will monitor how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ALN-ANG3

What this could lead to

If successful, this could lead to a new treatment for high cholesterol and triglycerides, potentially reducing heart disease risk.

What could go wrong

This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to lower lipids in later studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS WITH HYPERLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New Zealand Clinical Research

    Christchurch, Canterbury, 8013, New Zealand